EPIDEMIOLOGY OF POLIOMYELITIS IN THE UNITED-STATES ONE DECADE AFTER THE LAST REPORTED CASE OF INDIGENOUS WILD VIRUS-ASSOCIATED DISEASE

被引:223
作者
STREBEL, PM
SUTTER, RW
COCHI, SL
BIELLIK, RJ
BRINK, EW
KEW, OM
PALLANSCH, MA
ORENSTEIN, WA
HINMAN, AR
机构
[1] CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV IMMUNIZAT,ATLANTA,GA 30333
[2] CTR DIS CONTROL,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333
关键词
D O I
10.1093/clinids/14.2.568
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Poliomyelitis caused by wild poliovirus has been virtually nonexistent in the United States since 1980, and vaccine-associated paralytic poliomyelitis (VAPP) has emerged as the predominant form of the disease. We reviewed national surveillance data on poliomyelitis for 1960-1989 to assess the changing risks of wild-virus, vaccine-associated, and imported paralytic disease; we also sought to characterize the epidemiology of poliomyelitis for the period 1980-1989. The risk of VAPP has remained exceedingly low but stable since the mid-1960s, with approximately 1 case occurring per 2.5 million doses of oral poliovirus vaccine (OPV) distributed during 1980-1989. Since 1980 no indigenous cases of wild-virus disease, 80 cases of VAPP, and five cases of imported disease have been reported in the United States. Three distinct groups are at risk of vaccine-associated disease: recipients of OPV (usually infants receiving their first dose), persons in contact with OPV recipients (mostly unvaccinated or inadequately vaccinated adults), and immunologically abnormal individuals. Overall, 93% of cases in OPV recipients and 76% of vaccine-associated cases have been related to administration of the first or second dose of OPV. Our findings suggest that adoption of a sequential vaccination schedule (inactivated poliovirus vaccine followed by OPV) would be effective in decreasing the risk of VAPP while retaining the proven public health benefits of OPV.
引用
收藏
页码:568 / 579
页数:12
相关论文
共 57 条
[1]   POLIO VACCINES - TIME FOR A CHANGE IN IMMUNIZATION POLICY [J].
BEALE, AJ .
LANCET, 1990, 335 (8693) :839-842
[2]  
BRINK EW, 1989, CONT PEDIAT, V6, P28
[3]   MAPPING OF MUTATIONS ASSOCIATED WITH NEUROVIRULENCE IN MONKEYS INFECTED WITH SABIN 1 POLIOVIRUS REVERTANTS SELECTED AT HIGH-TEMPERATURE [J].
CHRISTODOULOU, C ;
COLBEREGARAPIN, F ;
MACADAM, A ;
TAFFS, LF ;
MARSDEN, S ;
MINOR, P ;
HORAUD, F .
JOURNAL OF VIROLOGY, 1990, 64 (10) :4922-4929
[4]   NATURAL VARIATION OF POLIOVIRUS NEUTRALIZATION EPITOPES [J].
CRAINIC, R ;
COUILLIN, P ;
BLONDEL, B ;
CABAU, N ;
BOUE, A ;
HORODNICEANU, F .
INFECTION AND IMMUNITY, 1983, 41 (03) :1217-1225
[5]   CHRONIC PROGRESSIVE POLIOMYELITIS SECONDARY TO VACCINATION OF AN IMMUNODEFICIENT CHILD [J].
DAVIS, LE ;
BODIAN, D ;
PRICE, D ;
BUTLER, IJ ;
VICKERS, JH .
NEW ENGLAND JOURNAL OF MEDICINE, 1977, 297 (05) :241-245
[6]   ERADICATION OF POLIOMYELITIS - PROGRESS IN THE AMERICA [J].
DEQUADROS, CA ;
ANDRUS, JK ;
OLIVE, JM ;
DASILVEIRA, CM ;
EIKHOF, RM ;
CARRASCO, P ;
FITZSIMMONS, JW ;
PINHEIRO, FP .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1991, 10 (03) :222-229
[7]  
ESTEVES K, 1988, B WORLD HEALTH ORGAN, V66, P739
[8]   COMPARATIVE-EVALUATION OF IMMUNIZATION WITH LIVE ATTENUATED AND ENHANCED-POTENCY INACTIVATED TRIVALENT POLIOVIRUS VACCINES IN CHILDHOOD - SYSTEMIC AND LOCAL IMMUNE-RESPONSES [J].
FADEN, H ;
MODLIN, JF ;
THOMS, ML ;
MCBEAN, AM ;
FERDON, MB ;
OGRA, PL .
JOURNAL OF INFECTIOUS DISEASES, 1990, 162 (06) :1291-1297
[9]  
Foote F M, 1973, Conn Med, V37, P643
[10]   NEUROLOGIC COMPLICATIONS IN ORAL POLIO VACCINE RECIPIENTS [J].
GAEBLER, JW ;
KLIMAN, MB ;
FRENCH, MLV ;
CHASTAIN, G ;
BARRETT, C ;
GRIFFIN, C .
JOURNAL OF PEDIATRICS, 1986, 108 (06) :878-881